PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 134 filers reported holding PARATEK PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $108,000 | -65.2% | 42,154 | -73.7% | 0.00% | -71.4% |
| Q2 2022 | $310,000 | -48.6% | 160,420 | -21.0% | 0.01% | -50.0% |
| Q1 2022 | $603,000 | -2.3% | 203,083 | +235.7% | 0.01% | +16.7% |
| Q2 2018 | $617,000 | -88.3% | 60,500 | -71.3% | 0.01% | -84.8% |
| Q3 2017 | $5,285,000 | +605.6% | 210,550 | +440.5% | 0.08% | +618.2% |
| Q1 2017 | $749,000 | +49.5% | 38,953 | +1.2% | 0.01% | +37.5% |
| Q3 2016 | $501,000 | – | 38,503 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |